![]() ![]() ![]() In our cohort, anti-MCV Ab disappearance was not linked to clinical and radiological improvement.Ĭonclusion: Different from anti-CCP Ab, anti-MCV Ab in sera from RA patients can disappear in a year. Continuous biological disease-modifying anti-rheumatic drug use, prednisolone dose (≥5.0 mg daily), and low KL-6 level (<191 U/mL) were determined as predicting factors of anti-MCV disappearance by multivariable analysis. Results: While anti-CCP positivity rate did not change during the year, anti-MCV Ab changed from positive to negative in 18 patients (=19.0%). Predicting factors of anti-MCV disappearance were determined by multivariable analysis. The association of anti-MCV disappearance with disease activity, treatment, interstitial lung disease (ILD), and serum markers of ILD were retrospectively examined. Titers of anti-MCV Ab and anti-cyclic citrullinated peptide (anti-CCP) Ab for 20 were measured. Methods: In 2013, 95 RA patients whose Disease Activity Score with erythrocyte sedimentation rate were moderate to severe (DAS28-ESR ≥3.2) at baseline were enrolled. Objectives: We aimed to determine the predicting factors for disappearance of anti-mutated citrullinated vimentin antibody (anti-MCV Ab) in sera from rheumatoid arthritis (RA) patients.
0 Comments
Leave a Reply. |